Q1 FY27 results analysis · August 11, 2026

Zydus Lifesciences Q1 FY27 Results Analysis: PAT Falls 36%, EBITDA Margin Compresses 770 bps (ZYDUSLIFE)

−35.9%PAT year on year, Rs. 939.80 Cr
Cofacto ResearchPublished August 11, 20262 min readNeutral read
Quick summary

Zydus Lifesciences Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 8,017.00 Cr (+21.96% YoY) and PAT growth of -35.93% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 11, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 8,017.00 Cr (+21.96% YoY)
PAT (Q1)Rs. 939.80 Cr (-35.93% YoY)
EBITDA margin24.07% (-770 bps YoY)
EPS (Q1)Rs. 9.35 (-35.87% YoY)
Market capRs. 117,526.90 Cr
CMPRs. 1,180.00

Quarter Snapshot

Revenue grew 22% YoY to a record Rs.8,017 Cr, driven by acquisitions, but margins compressed sharply (EBITDA margin down 770 bps) and PAT declined 36% due to integration costs, higher employee and finance costs, and US generic pricing pressure. Management's FY27 guidance of >24% EBITDA margin was achieved at the lower end, but organic pharma profitability remains under strain.

Key Investment Insights

Key Positives

  • Consolidated revenue grew 21.96% YoY to Rs.8,017.0 Cr, highest Q1 revenue on record
  • Consumer products revenue surged 67.45% YoY to Rs.1,435.9 Cr, driven by Comfort Click acquisition
  • Medical technologies revenue increased from Rs.2 Cr to Rs.283 Cr due to Amplitude Surgical consolidation
  • Pharma segment revenue grew 10.22% YoY to Rs.6,298.1 Cr despite US generic pricing pressure
  • Company completed Assertio acquisition on June 16, 2026, adding ~15 days of revenue
  • Normalized PAT (excluding exceptional items) estimated at Rs.953.1 Cr

Risk Factors

  • EBITDA margin compressed 770 bps YoY to 24.07%
  • PAT (to owners) declined 35.93% YoY to Rs.939.8 Cr
  • Pharma segment EBIT margin fell 1,263 bps YoY to 19.77% due to US generic competition and acquisition costs
  • Finance costs surged 84.2% YoY to Rs.156 Cr due to acquisition debt
  • Employee costs rose 36.1% YoY, outpacing revenue growth
  • Depreciation & amortisation jumped 133% YoY to Rs.555 Cr, partly due to Mirabegron amortisation

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.